MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Free Cash flow
-$37,138K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Maturities of investments
    • Share-based compensation expense
    • Accounts payable
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Inventory, net
    • Purchases of investments
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-44,741
-8,275
-40,371
-38,000
Depreciation
2,321
2,200
2,736
2,461
Amortization of intangible assets
1,020
1,020
1,019
368,429
Amortization of right-of-use assets
664
849
894
921
Amortization of patent license
516
-
-
-
Share-based compensation expense
9,263
4,459
9,588
10,984
Impairment charges
0
0
0
0
Merger-related compensation expense
-
-
0
-
Loss on extinguishment of debt
-
-
0
-
Gain on debt restructuring
-
-
0
-
Gain on disposal of assets
0
48,100
-
-
Accretion of discount on marketable securities, net
220
295
460
923
Change in the estimated fair value of contingent consideration
0
0
0
0
Inventory provision
1,363
54
-200
1,226
Deferred income taxes
0
0
0
0
Other
-225
-225
-232
-397
Accounts receivable, net
1,754
-6,098
4,832
-1,641
Inventory, net
11,261
3,206
-3,507
1,058
Prepaid expenses and other assets
-1,859
2,288
-717
-988
Accounts payable
5,478
-4,322
1,721
1,266
Accrued expenses
-2,077
314
4,554
1,011
Deferred revenue
-442
19
-584
-123
Operating lease liabilities
1,469
1,425
1,384
1,069
Contingent consideration liability
-
-
0
-
Other liabilities
734
5,132
1,026
-1,587
Net cash used in operating activities
-35,583
-44,691
-19,069
-18,707
Proceeds from disposal of assets
0
50,000
-
-
Payment for waiver of milestone obligation
0
1,900
-
-
Purchases of property and equipment
1,555
3,043
861
-86
Purchases of intangible assets
0
5,000
0
0
Cash paid for purchases of acquired entities, net of cash acquired
-
-
0
-
Purchase of patent license
2,056
-
-
-
Purchases of investments
5,099
52,448
33,094
65,825
Sales of investments
-
-
0
0
Maturities of investments
48,781
48,250
59,984
84,641
Net cash provided by investing activities
40,071
35,859
26,029
18,902
Proceeds from issuance of common stock under equity offerings, net of issuance costs
-
-
0
-
Proceeds from issuance of common stock from equity plans
255
1,437
0
1,469
Payment of debt issuance costs
-
-
0
-
Payment of contingent consideration
-
-
0
-
Payments made in conjunction with convertible notes exchange
-
-
0
-
Notes payable principal payoff
-
-
0
0
Net cash provided by financing activities
255
1,437
0
1,469
Net decrease in cash, cash equivalents, and restricted cash
4,743
-7,395
6,960
1,664
Cash, cash equivalents, and restricted cash at beginning of period
57,864
65,259
58,299
57,592
Cash, cash equivalents, and restricted cash at end of period
62,607
-
-
-
Cash and cash equivalents at end of period
61,003
-
-
-
Restricted cash at end of period
1,604
-
-
-
Cash, cash equivalents, and restricted cash at end of period
62,607
57,864
65,259
58,299
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Maturities of investments$48,781K (-75.04%↓ Y/Y)Proceeds from issuance ofcommon stock from...$255K (-86.98%↓ Y/Y)Net cash provided byinvesting activities$40,071K (-43.18%↓ Y/Y)Net cash provided byfinancing activities$255K (-86.98%↓ Y/Y)Canceled cashflow$8,710K Net decrease incash, cash...$4,743K (595.61%↑ Y/Y)Canceled cashflow$35,583K Purchases of investments$5,099K (-95.68%↓ Y/Y)Purchase of patentlicense$2,056K Purchases of property andequipment$1,555K (-19.80%↓ Y/Y)Share-based compensationexpense$9,263K (-56.09%↓ Y/Y)Accounts payable$5,478K (1184.75%↑ Y/Y)Depreciation$2,321K (-70.21%↓ Y/Y)Prepaid expenses andother assets-$1,859K (72.70%↑ Y/Y)Operating leaseliabilities$1,469K (184.91%↑ Y/Y)Inventory provision$1,363K (-84.04%↓ Y/Y)Amortization of intangibleassets$1,020K (-99.72%↓ Y/Y)Other liabilities$734K (216.14%↑ Y/Y)Amortization of right-of-useassets$664K (-69.29%↓ Y/Y)Amortization of patentlicense$516K Other-$225K (78.75%↑ Y/Y)Net cash used inoperating activities-$35,583K (51.54%↑ Y/Y)Canceled cashflow$24,912K Net loss-$44,741K (90.44%↑ Y/Y)Inventory, net$11,261K (191.13%↑ Y/Y)Accrued expenses-$2,077K (13.71%↑ Y/Y)Accounts receivable, net$1,754K (-62.94%↓ Y/Y)Deferred revenue-$442K (-154.70%↓ Y/Y)Accretion of discount onmarketable securities, net$220K (-92.62%↓ Y/Y)

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)